Abstract
Background: The prevalence of undefined pancreatic cystic neoplasms (PCNs) is high in the general population, increasing with patient age. PCNs account for different biological entities with different potential for malignant transformation. The clinician must balance his or her practice between the risk of surgical overtreatment and the error of keeping a malignant lesion under surveillance. Methods: We review and discuss the clinical management of PCNs. Specifically, we analyze the main features of PCNs from the surgeon’s point of view, as they present in the outpatient clinic. We also review the different consensus guidelines, address recent controversies in the literature, and present the current clinical practice at 4 different European Centers for pancreatic surgery. Results: The main features of PCNs were analyzed from the surgeon’s point of view as they present in the outpatient clinic. All aspects of surgical management were discussed, from indications for surgery to intraoperative management and surveillance strategies. Conclusions: Management of PCNs requires a selective approach with the aim of minimizing clinically relevant diagnostic mistakes. Through the evaluation of clinical and radiological features of a PCN, the surgeon can elaborate on a diagnostic hypothesis and assess malignancy risk, but the final decision should be tailored to the individual patient’s need.
References
1.
Farrell JJ: Prevalence, diagnosis and management of pancreatic cystic neoplasms: current status and future directions. Gut Liver 2015; 9: 571–589.
2.
Lee KS, Sekhar A, Rofsky NM, et al: Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 2010; 105: 2079–2084.
3.
Gaujoux S, Brennan MF, Gonen M, et al: Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg 2011; 212: 590–600.
4.
Hruban RH, Kloeppel G, Bofetta P, et al: Tumours of the pancreas; in Bosman FT, Carneiro F, Hruban RH (eds): WHO Classification of Tumours of the Digestive System (ed 4). Lyon, International Agency for Research on Cancer, 2010, pp 280–330.
5.
Tanaka M, Fernandez-del Castillo C, Adsay V, et al: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183-197
6.
Del Chiaro M, Segersvärd R, Pozzi Mucelli R, et al: Comparison of preoperative conference-based diagnosis with histology of cystic tumors of the pancreas. Ann Surg Oncol 2014; 21: 1539–1544.
7.
Salvia R, Malleo G, Marchegiani G, et al: Pancreatic resections for cystic neoplasms: from the surgeon’s presumption to the pathologist’s reality. Surgery 2012; 152(3 suppl 1):S135–S142.
8.
Cho CS, Russ AJ, Loeffler AG, et al: Preoperative classification of pancreatic cystic neoplasms: the clinical significance of diagnostic inaccuracy. Ann Surg Oncol 2013; 20: 3112–3119.
9.
Tanaka M, Chari S, Adsay V, et al: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6: 17–32.
10.
Tanaka M, Fernandez-del Castillo C, Adsay V, et al: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183–197
11.
Tanaka M, Fernández-Del Castillo C, Kamisawa T, et. Al: Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017; 17: 738–753.
12.
Vege SS, Ziring B, Jain R, et al; Clinical Guidelines Committee; American Gastroenterology Association: American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015; 148: 819–22; quize12–23.
13.
Del Chiaro M, Verbeke C, Salvia R, et al; European Study Group on Cystic Tumours of the Pancreas: European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis 2013; 45: 703–711.
14.
European Study Group on Cystic Tumours of the Pancreas: European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018; 67: 789–804.
15.
Jang DK, Song BJ, Ryu JK, et al: Preoperative diagnosis of pancreatic cystic lesions: the accuracy of endoscopic ultrasound and cross-sectional imaging. Pancreas 2015; 44: 1329–1333.
16.
Lee HJ, Kim MJ, Choi JY, et al: Relative accuracy of CT and MRI in the differentiation of benign from malignant pancreatic cystic lesions. Clin Radiol 2011; 66: 315–321.
17.
Sahani DV, Kambadakone A, Macari M, et al: Diagnosis and management of cystic pancreatic lesions. AJR Am J Roentgenol 2013; 200: 343–354.
18.
Waters JA, Schmidt CM, Pinchot JW, et al: CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg 2008; 12: 101–109
19.
Harima H: Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography. World J Gastroenterol 2015; 21: 6252–6260.
20.
Cizginer S, Turner BG, Bilge AR, et al: Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas 2011; 40: 1024–1028.
21.
Sedlack R, Affi A, Vazquez-Sequeiros E, et al: Utility of EUS in the evaluation of cystic pancreatic lesions. Gastrointest Endosc 2002; 56: 543–547.
22.
Brugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, et al: Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004; 126: 1330–1336.
23.
Jang JY, Park T, Lee S, et al: Proposed nomogram predicting the individual risk of malignancy in the patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2017; 266: 1062–1068.
24.
Wang W, Zhang L, Chen L, et al: Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Biomed Rep 2015; 3: 43–50.
25.
Kim JR, Jang JY, Kang MJ, et al: Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19–9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas. J Hepatobiliary Pancreat Sci 2015; 22: 699–707.
26.
Masica DL, Dal Molin M, Wolfgang CL: A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. J Am Med Inform Assoc 2017; 24: 145–152.
27.
Jang JY, Park T, Lee S: Proposed nomogram predicting the individual risk of malignancy in the patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2017; 266: 1062–1068.
28.
Crippa S, Bassi C, Salvia, et al: Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. Gut 2017; 66: 495–506.
29.
Mukewar S, De Pretis N, Aryal-khanal A, et al: Fukuoka criteria accurately predict risk for adverse outcomes during follow-up of pancreatic cysts presumed to be intraductal papillary mucinous neoplasms. Gut 2017; 66: 1811–1817.
30.
Han Y, Lee H, Kang JS, et al: Progression of pancreatic branch duct intraductal papillary mucinous neoplasm associates with cyst size. Gastroenterology 2018; 154: 576–584.
31.
Roch AM, Parikh JA, Al-Haddad MA, et al: Abnormal serum pancreatic enzymes, but not pancreatitis, are associated with an increased risk of malignancy in patients with intraductal papillary mucinous neoplasms. Surgery 2014; 156: 923–930.
32.
Rivera JA, Fernández-del Castillo C, Pins M, et al: Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity. Ann Surg 1997; 225: 637–646.
33.
Shin SH, Han DJ, Park KT, et al: Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg 2010; 34: 776–783.
34.
Sahora K, Mino-Kenudson M, Brugge W, et al: Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg 2013; 258: 466–475.
35.
Nguyen AH, Toste PA, Farrell JJ, et al: Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer. J Gastrointest Surg 2015; 19: 258–265.
36.
Roch AM, Ceppa EP, DeWitt JM, et al: International consensus guidelines parameters for the prediction of malignancy in intraductal papillary mucinous neoplasm are not properly weighted and are not cumulative. HPB (Oxford) 2014; 16: 929–935.
37.
Robles EP, Maire F, Cros J, et al: Accuracy of 2012 international consensus guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas. United European Gastroenterol J 2016; 4: 580–586.
38.
Del Chiaro M, Ateeb Z, Hansson MR, et al: Survival analysis and risk for progression of intraductal papillary mucinous neoplasia of the pancreas (IPMN) under surveillance: a single-institution experience. Ann Surg Oncol 2017; 24: 1120–1126.
39.
Jang JY, Park T, Lee S, et al: Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. Br J Surg 2014; 101: 686–692.
40.
Ohtsuka T, Kono H, Nagayoshi Y, et al: An increase in the number of predictive factors augments the likelihood of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas. Surgery 2012; 151: 76–83.
41.
Kang MJ, Jang JY, Kim SJ, et al: Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 2011; 9: 87–93.
42.
Kwong WT, Lawson RD, Hunt G, et al: Rapid growth rates of suspected pancreatic cyst branch duct intraductal papillary mucinous neoplasms predict malignancy. Dig Dis Sci 2015; 60: 2800–2806.
43.
Marchegiani G, Andrianello S, Borin A, et al: Systematic review, meta-analysis, and a high-volume center experience supporting the new role of mural nodules proposed by the updated 2017 international guidelines on IPMN of the pancreas. Surgery 2018; 163: 1272–1279.
44.
Crippa S, Pergolini I, Rubini C, et al: Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. Surgery 2016; 159: 1041–1049.
45.
Hackert T, Fritz S, Klauss M, et al: Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg 2015; 262: 875–880.
46.
Laurent L, Vullierme MP, Rebours V, et al: Estimation of the prevalence of intraductal papillary mucinous neoplasm of the pancreas in the French population through patients waiting for liver transplantation. United European Gastroenterol J 2017; 5: 499–503.
47.
Pergolini I, Sahora K, Ferrone CR, et al: Long-term risk of pancreatic malignancy in patients with branch duct intraductal papillary mucinous neoplasm in a referral center. Gastroenterology 2017; 153: 1284–1294.e1.
48.
Han Y, Lee H, Kang JS, et al: Progression of pancreatic branch duct intraductal papillary mucinous neoplasm associates with cyst size. Gastroenterology 2018; 154: 576–584.
49.
Lawrence SA, Attiyeh MA, Seier K, et al: Should patients with cystic lesions of the pancreas undergo long-term radiographic surveillance: results of 3024 patients evaluated at a single institution. Ann Surg 2017; 266: 536–544.
50.
Ohno E, Hirooka Y, Kawashima H, et al: Natural history of pancreatic cystic lesions: a multicenter prospective observational study for evaluating the risk of pancreatic cancer. J Gastroenterol Hepatol 2018; 33: 320–328.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
